(Health Korea News / Lee Chang-yong) It is predicted that the 3D cell culture market will grow significantly in the field of organ transplantation. This is because 3D cell culture technology not only has a lower risk of failure compared to existing 2D culture methods, but can also replace animal testing.
On the 23rd, the Korea Health Industry Development Institute (KHIDI) released a report titled ‘3D Cell Culture Market Growth Prospects According to New Drug Development’ containing the above content.
According to the report, the global cell culture market size is expected to grow from USD 1.42 billion (KRW 1.9228 trillion) in 2022 to USD 5.29 billion (KRW 7.1634 trillion) in 2032.
The ever-improving cell culture technology has also led to the growth of the 3D cell culture market. The area where demand for this technology is particularly increasing is the field of organ transplantation. 3D cell culture technology has the advantage of superior predictability compared to existing 2D culture methods.
3D cell culture technologies that are receiving attention include hydrogel scaffolds, microchips, and 3D organoids, and among them, 3D organoids are receiving a lot of attention. Organoids are 3D cell tissues that have a structure, composition, and function similar to human organs, and are 3D biological organ analogues.
Using 3D organoids, cells similar to actual animal or human organs can be produced. Thanks to this feature, they can be used to test the effects of new drugs or develop new drugs. For example, in the case of cancer cell organoids, the accuracy of predictions when using anticancer drugs can be improved.
However, the technology with the highest market share is hydrogel scaffolds. Hydrogel scaffolds are structures made of hydrogel to make 3D cell culture more stable.
Hydrogel scaffolds are nests that help 3D cells to grow well in the body, and are usually made of biopolymers that mimic the extracellular matrix (ECM) of animals. They can closely replicate the microenvironment of tissues and organs, allowing for more accurate modeling of cell properties and the physiological responses that cells will exhibit.
The report also forecasts that the 3D cell culture market without scaffold addition will grow rapidly by 2033. This is because spheroids are gaining attention. Spheroids refer to circular collections of cells that exist as a mass of tissue. It is known that cells are self-generated within spheroids and can be created using various platforms.
As of 2023, the fields in which 3D cell culture technology has been studied the most are ▲cancer ▲stem cell research ▲tissue engineering. Among these, the cancer research field is showing the fastest growth. In cancer treatment, the use of spheroid and organoid methods can enable reliable screening of anticancer drugs, so it is expected that this technology will be utilized more actively in the future.
The country leading the way in 3D cell culture technology is the United States. Last August, Cell Microsystems, a cell biology company in the United States, opened a research center that can produce and test customized organoids using CellRaft technology to generate cell lines.
Last December, Danaher, a U.S. science and technology company, acquired Abcam for new drug development, life science research, and diagnostics. Abcam is a company that provides antibodies, reagents, biomarkers, and assays. Danaher aims to operate Abcam independently in the life science sector and accelerate new drug discovery.
In September 2022, Thermo Fisher Scientific, a U.S. company that develops and supplies cell culture and analysis equipment, launched the Cell Therapy System (CTS), a sustainable solution for large-scale cell culture.
As many American companies are active in the development of 3D cell culture, the United States also has the largest global market share. North America accounted for 42.01% of the 3D cell culture market in 2023. This is because a lot of money has been invested to research and develop effective alternatives to animal testing.
The Asia Pacific region is also expected to grow rapidly. Currently, countries such as ▲China ▲Japan ▲India are leading the market, and China in particular shows high growth potential because the Chinese government actively supports biomedical research and development.
Japan and India are also assessed to be contributing to the market growth in the Asia Pacific region due to ▲technological advancements ▲increased investment in medical infrastructure ▲increased preference for precision medicine and personalized treatment.
The report stated, “As the need for new drug discovery and new vaccine development increases due to the impact of COVID-19, the demand for 3D cell culture technology is also increasing,” and predicted that “the shift toward personalized research will accelerate in both industrial and academic fields, and 3D culture technology will become more important, especially in the pharmaceutical industry.”
Copyright © Health Korea News. Unauthorized reproduction and redistribution prohibited.
Source: www.hkn24.com
